Orphanet: Pesquisa simples
x

Pesquisar um ensaio clínico

* (*) campo(s) de preenchimento obrigatório

18 Resultado(s)

Ensaio em fase de recrutamento = Ensaio em fase de recrutamento; Ensaio a decorrer = Ensaio a decorrer; Financiado por um membro do IRDiRC =

Ensaio (s) clínico (s) nacional (is)

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658 (morpholino oligomer directed against exon 51)
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio em fase de recrutamentoEnsaio a decorrerFinanciado por um membro do IRDiRCA Phase III Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio a decorrerAn open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

FOR-DMD: Duchenne muscular dystrophy: doubleblind randomized trial to find optimum steroid regimen (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio a decorrerAn Open-Label Study for Previously Treated Ataluren (PTC124®) Patients with Nonsense Mutation Dystrophinopathy (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio a decorrerPTC124-GD-007-DMD: A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio em fase de recrutamentoEnsaio a decorrerPhase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Ensaio (s) clínico (s) multinacional (ais)

BELGICA

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Financiado por um membro do IRDiRCSCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
European Commission
DG Research - Directorate General for Research

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

Financiado por um membro do IRDiRCSCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine